|
|
|
|
|
Pharmaceutical Market Research
|
| Alcon Inc.: PharmaVitae Profile |
|
| Table of Contents Published: 2010/01 Price: US $ 5700 Published by: Datamonitor |
| This analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal ... |
| Developing Managed Care Pull-Through Excellence |
|
| Table of Contents Published: 2010/01 Price: US $ 5200 Published by: Best Practices, LLC |
| This Best Practices, LLC research investigates pull-through challenges and the best practices that companies have developed to overcome them. The research will enable pharmaceutical, bio-pharma and medical device company leadership to identify program gap ... |
| Consumer Choices in Healthcare - US - January 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 3995 Published by: Mintel International Group Ltd, |
| The Great Recession, high unemployment rates, rising premiums, an aging population, and more are changing the face of healthcare in America. Providers in the category must understand these challenges and appropriate responses if they are to flourish. ... |
| The Pharmaceuticals Consumer - US - January 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 3995 Published by: Mintel International Group Ltd, |
| The pharmaceutical industry seems to be continually at battle for consumer trust, having to combat an onslaught of legislative and legal battles while doing a marketing dance around the elephant in the room of fair balance regulations. ... |
| Best Practices in Recruitment for Medical Education Programs |
|
| Table of Contents Published: 2010/01 Price: US $ 3895 Published by: Best Practices, LLC |
| New regulations and guidelines regarding medical education programs have made it more challenging to recruit attendees for both certified CME and non-CME programs.
This benchmark research project identifies emerging trends in recruiting attendees for ... |
| Merck KGaA-Company Report |
|
| Table of Contents Published: 2010/01 Price: US $ 750 Published by: Life Science Analytics |
| Merck KGaA-Company Report is a private Company Report that provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies. ... |
| Abbott Laboratories-Deals & Alliances Report |
|
| Table of Contents Published: 2010/01 Price: US $ 600 Published by: Life Science Analytics |
| Deals & Alliances Reports provide detail on a company's deals and deal partners. Each report contains information on size of deals, deals by therapeutic area and stage of development, product and technology. ... |
| Renal Cancer Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| There are today 149 (135) companies plus partners developing 188 (164) drugs targeting renal cancer in active development. In addition, the accumulated number of ceased drugs over the last years amount to another 46 (32) drugs. Renal Cancer Drug Pipeline ... |
| Radiation Therapy in Oncology Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| There are today 259 companies plus partners developing 275 radiation drugs in 520 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 125 drugs. Radiation Therapy In Oncology Drug Pip ... |
| Prostate Cancer Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| There are today 294 (255) companies plus partners developing 363 (301) drugs targeting prostate cancer in active development. In addition, the accumulated number of ceased drugs over the last years amount to another 148 (122) drugs. Prostate Cancer Drug P ... |
| Peptides in Oncology Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| There are today 201 (124) companies plus partners developing 203 (137) peptide drugs in 355 (226) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 109 (56) drugs. Peptides In Oncol ... |
| Pancreatic Cancer Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| There are today 209 (172) companies plus partners developing 237 (191) drugs targeting pancreatic cancer in active development. In addition, the accumulated number of ceased drugs over the last years amount to another 77 (53) drugs. Pancreatic Cancer Drug ... |
| Ovarian Cancer Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for existing and pipeline drugs. ... |
| Neuroendocrine Tumors Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 1449 Published by: BioSeeker Group AB |
| There are today 37 companies plus partners developing 51 neuroendocrine tumor drugs in 63 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 2 drugs. Neuroendocrine Tumors Drug Pipel ... |
| Melanoma Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.
There are today 218 (19 ... |
| Liver Cancer Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 1449 Published by: BioSeeker Group AB |
| There are today 136 (113) companies plus partners developing 154 (107) drugs targeting liver cancer in active development. In addition, the accumulated number of ceased drugs over the last years amount to another 42 (34) drugs. Liver Cancer Drug Pipeline ... |
| Hematological Cancers Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2899 Published by: BioSeeker Group AB |
| Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity.
There are today 324 (263) companies plus partners developing 490 (364) hematological cancer drugs in ... |
| Head and Neck Cancer Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| There are today 111 companies plus partners developing 122 drugs targeting head and neck cancer in active development. In addition, the accumulated number of ceased drugs over the last years amount to another 33 drugs. Head And Neck Cancer Drug Pipeline U ... |
| Gene Therapy in Oncology Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| There are today 92 companies plus partners developing 118 gene therapy drugs in 230 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 49 drugs. Gene Therapy In Oncology Drug Pipelin ... |
| Cytokine Therapy in Oncology Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 1449 Published by: BioSeeker Group AB |
| There are today 69 companies plus partners developing 80 cytokine drugs in 143 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 8 drugs. Cytokine Therapy In Oncology Drug Pipeline ... |
| Colorectal Cancer Drug Pipeline Update 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 2174 Published by: BioSeeker Group AB |
| Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease man ... |
|
|
View Cart
